Page 4 - Interferon Alpha News Today : Breaking News, Live Updates & Top Stories | Vimarsana

URL copied Image Source : AP A health worker prepares to administer the COVAXIN vaccine for COVID-19 to a man at an indoor stadium. (Representational image) Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, 'Virafin' for treating moderate COVID-19 infection in adults. Earlier, Zydus Cadila announced that its Phase III clinical trials with Pegylated Interferon Alpha 2b, PegiHep has shown promising results in treating Covid-19. In what could be a breakthrough in the disease management of Co...

Zydus Cadila seeks DCGI nod for use of PegiHep in Covid-19 treatment April 05, 2021 Phase-3 clinical trials showed promising results in treating Covid-19 In what could be termed a major breakthrough in the disease management of Covid-19, drug major Cadila Healthcare Limited (Zydus Cadila) has said that initial Phase-III clinical trials of Pegylated Interferon Alpha 2b, PegiHep, showed promising results in the treatment of the novel coronavirus. The interim results indicate that PegIFN, when administered early on, could help patients recover faster, avoiding many of the complications seen in ...

Zydus' COVID-19 drug shows promise in Phase 3 trials; seeks DCGI nod Over 91.15% of patients treated with PegIFN were found to be RT PCR negative by day 7 as compared to 78.90 per cent on the 'standard of care' arm; PegIFN reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate COVID-19 patients BusinessToday.In | April 5, 2021 | Updated 12:51 IST Interim results show PegIFN could help patients recover faster, avoiding complications seen in the advanced stages Zydus Cadila announced on Monday, April 5 that it has sought approval from drug regulator DCGI (Drugs Cont...

New Delhi (India) [India], April 5 (ANI): Pharmaceutical Company Zydus Cadila on Monday informed that it has sought approval of the Drugs Controller General of India (DGCI) for using its hepatitis drug for the treatment of coronavirus.

With the phase-3 clinical trials of its Pegylated Interferon Alpha 2b therapy, PegiHep, showing promising results, Cadila Healthcare Ltd (Zydus Cadila) has applied for an approval for additional indication with the Drugs Controller General of India (DCGI) for the use of PegIFN in the treatment of Covid-19. In what could be a breakthrough in the disease management of Covid-19, the interim results indicate that PegIFN when administered early on, could help patients recover faster and avoid much of the complications seen in the advanced stages of the disease. According to Zydus Cadila, PegIFN...